Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

被引：13

作者：

Merz, Maximilian ^{[1
]}

Salwender, Hans ^{[2
]}

Haenel, Mathias ^{[3
]}

Mai, Elias K. ^{[1
]}

Bertsch, Uta ^{[1
,4
]}

Kunz, Christina ^{[5
]}

Hielscher, Thomas ^{[5
]}

Blau, Igor W. ^{[6
]}

Scheid, Christof ^{[7
]}

Hose, Dirk ^{[1
]}

Seckinger, Anja ^{[1
]}

Jauch, Anna ^{[8
]}

Hillengass, Jens ^{[1
]}

Raab, Marc S. ^{[1
]}

Schurich, Baerbel ^{[1
]}

Munder, Markus ^{[9
]}

Brossart, Peter ^{[10
]}

Gerecke, Christian ^{[11
]}

Lindemann, Hans-Walter ^{[12
]}

Zeis, Matthias ^{[13
]}

Weisel, Katja ^{[14
]}

Duerig, Jan ^{[15
]}

Goldschmidt, Hartmut ^{[1
,4
]}

机构：

[1] Univ Heidelberg Hosp, Heidelberg, Germany

[2] Asklepios Hosp Hamburg Altona, Hamburg, Germany

[3] Klinikum Chemnitz, Chemnitz, Germany

[4] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany

[5] German Canc Res Ctr Heidelberg, Heidelberg, Germany

[6] Charite Univ Med Berlin, Berlin, Germany

[7] Univ Hosp Cologne, Cologne, Germany

[8] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[9] Univ Med Ctr Mainz, Mainz, Germany

[10] Univ Hosp Bonn, Bonn, Germany

[11] Helios Hosp Berlin Buch, Berlin, Germany

[12] Kath Krankenhaus Hagen, Hagen, Germany

[13] Asklepios Hosp St Georg Hamburgy, Hamburg, Germany

[14] Univ Tubingen Hosp, Tubingen, Germany

[15] Univ Hosp Essen, Essen, Germany

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 12期

关键词：

RELAPSED MULTIPLE-MYELOMA; MELPHALAN-PREDNISONE; INDUCTION; MAINTENANCE; TRANSPLANTATION; REVERSIBILITY; LENALIDOMIDE; RISK;

D O I：

10.3324/haematol.2016.151266

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E485 / E487

页数：3

共 15 条

[1] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [J].

Arnulf, Bertrand ;

Pylypenko, Halyna ;

Groslcki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

van de Velde, Helgi ;

Feng, Huaibao ;

Cakana, Andrew ;

Deraedt, William ;

Moreau, Philippe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1925-1928

[2] Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study [J].

Dimopoulos, Meletios A. ;

Mateos, Maria-Victoria ;

Richardson, Paul G. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Palumbo, Antonio ;

Wu, Ka Lung ;

Esseltine, Dixie-Lee ;

Liu, Kevin ;

Deraedt, William ;

Cakana, Andrew ;

van de Velde, Helgi ;

San Miguel, Jesus F. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) :23-31

[3] Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density [J].

Kosturakis, Alyssa K. ;

He, Zijing ;

Li, Yan ;

Boyette-Davis, Jessica A. ;

Shah, Nina ;

Thomas, Sheeba K. ;

Zhang, Haijun ;

Vichaya, Elisabeth G. ;

Wang, Xin Shelley ;

Wendelschafer-Crabb, Gwen ;

Kennedy, William R. ;

Simone, Donald A. ;

Cleeland, Charles S. ;

Dougherty, Patrick M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) :3156-+

[4] Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma [J].

Mai, E. K. ;

Bertsch, U. ;

Duerig, J. ;

Kunz, C. ;

Haenel, M. ;

Blau, I. W. ;

Munder, M. ;

Jauch, A. ;

Schurich, B. ;

Hielscher, T. ;

Merz, M. ;

Huegle-Doerr, B. ;

Seckinger, A. ;

Hose, D. ;

Hillengass, J. ;

Raab, M. S. ;

Neben, K. ;

Lindemann, H-W ;

Zeis, M. ;

Gerecke, C. ;

Schmidt-Wolf, I. G. H. ;

Weisel, K. ;

Scheid, C. ;

Salwender, H. ;

Goldschmidt, H. .

LEUKEMIA, 2015, 29 (08) :1721-1729

[5] Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain [J].

Mangiacavalli, Silvia ;

Corso, Alessandro ;

De Amici, Mara ;

Varettoni, Marzia ;

Alfonsi, Enrico ;

Lozza, Alessandro ;

Lazzarino, Mario .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (06) :916-918

[6] Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy [J].

Mateos, Maria-Victoria ;

Bringhen, Sara ;

Richardson, Paul G. ;

Jose Lahuerta, Juan ;

Larocca, Alessandra ;

Oriol, Albert ;

Boccadoro, Mario ;

Garcia-Sanz, Ramon ;

Di Raimondo, Francesco ;

Esseltine, Dixie-Lee ;

van de Velde, Helgi ;

Desai, Avinash ;

Londhe, Anil ;

San Miguel, Jesus F. ;

Palumbo, Antonio .

HAEMATOLOGICA, 2014, 99 (06) :1114-1122

[7] Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial [J].

Merz, Maximilian ;

Salwender, Hans ;

Haenel, Mathias ;

Mai, Elias K. ;

Bertsch, Uta ;

Kunz, Christina ;

Hielscher, Thomas ;

Blau, Igor W. ;

Scheid, Christof ;

Hose, Dirk ;

Seckinger, Anja ;

Jauch, Anna ;

Hillengass, Jens ;

Raab, Marc S. ;

Schurich, Baerbel ;

Munder, Markus ;

Schmidt-Wolf, Ingo G. H. ;

Gerecke, Christian ;

Lindemann, Hans-Walter ;

Zeis, Matthias ;

Weisel, Katja ;

Duerig, Jan ;

Goldschmidt, Hartmut .

HAEMATOLOGICA, 2015, 100 (07) :964-969

[8] Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy [J].

Minarik, Jiri ;

Pavlicek, Petr ;

Pour, Ludek ;

Pika, Tomas ;

Maisnar, Vladimir ;

Spicka, Ivan ;

Jarkovsky, Jiri ;

Krejci, Marta ;

Bacovsky, Jaroslav ;

Radocha, Jakub ;

Straub, Jan ;

Kessler, Petr ;

Wrobel, Marek ;

Walterova, Lenka ;

Sykora, Michal ;

Obernauerova, Jarmila ;

Brozova, Lucie ;

Gregora, Evzen ;

Adamova, Dagmar ;

Gumulec, Jaromir ;

Adam, Zdenek ;

Scudla, Vlastimil ;

Hajek, Roman .

PLOS ONE, 2015, 10 (04)

[9] Obesity and peripheral neuropathy risk: a dangerous liaison [J].

Miscio, G ;

Guastamacchia, G ;

Brunani, A ;

Priano, L ;

Baudo, S ;

Mauro, A .

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2005, 10 (04) :354-358

[10] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [J].

Moreau, Philippe ;

Pylypenko, Halyna ;

Grosicki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

Grishunina, Maria ;

Rekhtman, Grigoriy ;

Masliak, Zvenyslava ;

Robak, Tadeusz ;

Shubina, Anna ;

Arnulf, Bertrand ;

Kropff, Martin ;

Cavet, James ;

Esseltine, Dixie-Lee ;

Feng, Huaibao ;

Girgis, Suzette ;

van de Velde, Helgi ;

Deraedt, William ;

Harousseau, Jean-Luc .

LANCET ONCOLOGY, 2011, 12 (05) :431-440

← 1 2 →